Panoramica

Idoneità

Dettagli del Disegno

Bracci e Interventi

Misure di Esito

Siti dello Studio

Fonte: NCT06368817

Reclutamento in corso

A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma

Interventistico

Fase 2

Newark Beth Israel Medical Center

Sponsor: Children's Oncology Group

Ultimo Aggiornamento: 4 maggio 2026

Avviso - Le informazioni provengono da registri pubblici e potrebbero non riflettere i cambiamenti in tempo reale presso il centro locale.

This phase II trial studies how well lower dose radiotherapy after chemotherapy (Carboplatin & Etoposide) works in treating children with central nervous system (CNS) germinomas. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Researchers want to see if lowering the dose of standard radiotherapy (RT) after chemotherapy can help get rid of CNS germinomas with fewer long-term side effects.

Mostra Descrizione Dettagliata

Categoria di Trattamento

Chemioterapia, Procedura, Altri, Radioterapia

Mutazioni richieste

Nessuno

Studio Iniziato

22 ottobre 2024

Ultimo Aggiornamento dello Sponsor

4 maggio 2026

Completamento Stimato

4 novembre 2033

Contatto dello studio

Idoneità

Criteri di Inclusione

* Patients must be ≥ 3 years and < 30 years at the time of study enrollment

* Patients must be newly-diagnosed primary localized germinoma of the suprasellar and/or pineal region by pathology and/or serum and/or CSF hCGbeta 5-50 mIU/mL AND institutional normal AFP (or ≤ 10 ng/mL if no institutional normal exists), including tumors with contiguous ventricular or unifocal parenchymal extension. No histologic confirmation required

* Patients with EITHER (A) bifocal (pineal + suprasellar) involvement OR (B) pineal lesion with diabetes insipidus (DI) AND hCGbeta ≤ 100 mIU/mL in serum and/or CSF AND institutional normal AFP (or ≤ 10 ng/mL if no institutional normal exists) in both serum and CSF. No histologic confirmation required

* Patients with hCGbeta 51-100 mIU/mL in serum and/or CSF and institutional normal AFP (or ≤ 10 ng/mL if no institutional normal exists) in both serum and CSF. Histologic confirmation of germinoma IS required

* Patients with germinoma of the basal ganglia and or/thalamic primary sites are eligible

* Patients with metastatic germinoma including non-contiguous disease or distant disease in the brain, ventricles, or spine are eligible

* Patients with germinoma admixed with mature teratoma are eligible

* Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2. Use Karnofsky for patients > 16 years of age and Lansky for patients ≤ 16 years of age

* Patients must have eligibility confirmed by Rapid Central Imaging Review performed on APEC14B1-CNS

* Imaging studies must be obtained within 31 days prior to study enrollment and start of protocol therapy. (Note: for patients that have had surgery and post-operative imaging performed, it is the post-operative MRI that must be obtained within 31 days prior to enrollment.)

* Patients must have a cranial magnetic resonance imaging (MRI) with and without gadolinium at diagnosis/prior to enrollment. If surgical resection is performed, patients must have pre-operative and post-operative brain MRI with and without gadolinium. The post-operative brain MRI should be obtained within 72 hours of surgery. If patient has a biopsy only, post-operative brain MRI is recommended but not required

* Patients must have a spine MRI with gadolinium obtained at diagnosis/prior to enrollment

* Patients must be enrolled, and protocol therapy must begin, no later than 31 days after definitive surgery or clinical diagnosis, whichever is later

* Patients must have eligibility confirmed by Rapid Central Tumor Marker Review performed on APEC14B1-CNS

* Lumbar CSF must be obtained prior to study enrollment unless medically contraindicated. If a patient undergoes surgery and lumbar CSF cytology cannot be obtained at the time of surgery, then it should be performed at least 10 days following surgery and prior to study enrollment. False positive cytology can occur within 10 days of surgery. Of note, lumbar CSF should not be performed prior to obtaining spine MRI, as this can make interpretation of the spine MRI less clear

* Patients must have CSF tumor markers obtained prior to study enrollment unless medically contraindicated. Ventricular CSF obtained at the time of CSF diversion procedure (if performed) is acceptable for tumor markers but lumbar CSF is preferred. In case CSF diversion and biopsy/surgery are combined, CSF tumor markers should be collected first. Ideally serum and CSF tumor markers should be collected at the same time and processed without delay

* For patients with solid tumors: Peripheral absolute neutrophil count (ANC) >= 1000/uL (Must be performed within 7 days prior to enrollment unless otherwise indicated)

* For patients with solid tumors: Platelet count >= 100,000/uL (transfusion independent) (Must be performed within 7 days prior to enrollment unless otherwise indicated)

* For patients with solid tumors: Hemoglobin >= 8.0 g/dL (may receive red blood cell [RBC] transfusions) (Must be performed within 7 days prior to enrollment unless otherwise indicated)

* For pediatric patients (age 3-17 years): A serum creatinine based on age/sex as follows (Must be performed within 7 days prior to enrollment unless otherwise indicated):

* Age: 3 to < 6 years; maximum serum creatinine (mg/dL): 0.8 (male); 0.8 (female)

* Age: 6 to < 10 years; maximum serum creatinine (mg/dL): 1 (male); 1 (female)

* Age: 10 to < 13 years; maximum serum creatinine (mg/dL): 1.2 (male); 1.2 (female)

* Age: 13 to < 16 years; maximum serum creatinine (mg/dL): 1.5 (male); 1.4 (female)

* Age: ≥ 17 years; maximum serum creatinine (mg/dL): 1.7 (male); 1.4 (female) OR a 24-hour urine creatinine clearance ≥ 70 mL/min/1.73 m^2 OR a glomerular filtration rate (GFR) ≥ 50 mL/min/1.73 m^2. GFR must be performed using direct measurement with a nuclear blood sampling method OR direct small molecule clearance method (iothalamate or other molecule per institutional standard).

* Note: Estimated GFR (eGFR) from serum or plasma creatinine, cystatin C or other estimates are not acceptable for determining eligibility.

* For adult patients (age 18 years or older) (Must be performed within 7 days prior to enrollment unless otherwise indicated):

* Creatinine clearance ≥ 70 mL/min, as estimated by the Cockcroft and Gault formula or a 24-hour urine collection. The creatinine value used in the calculation must have been obtained within 28 days prior to registration. Estimated creatinine clearance is based on actual body weight

* Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age (Must be performed within 7 days prior to enrollment unless otherwise indicated)

* Serum glutamic-pyruvic transaminase (SGPT) (alanine transaminase [ALT]) ≤ 135 U/L (Must be performed within 7 days prior to enrollment unless otherwise indicated)

* Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L

* No evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry > 94% if there is clinical indication for determination

* Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled

* CNS toxicity =< grade 2

* Patients must not be in status epilepticus, coma or assisted ventilation prior to study enrollment

* HIV-infected patients on effective anti-retroviral therapy with undetectable viral load are eligible for this study

Criteri di Esclusione

* Patients with any of the following malignant pathological elements are not eligible:

* Endodermal sinus (yolk sac)

* Embryonal carcinoma, choriocarcinoma

* Malignant/immature teratoma and mixed germ cell tumor (GCT) (i.e., may include some germinoma)

* Patients with only mature teratoma upon tumor sampling at diagnosis and negative tumor markers are not eligible

* Patients who have received any prior tumor-directed therapy for their diagnosis of germinoma other than surgical intervention and corticosteroids are not eligible

* Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required for female patients of childbearing potential.

* Note: Serum and urine pregnancy tests may be falsely positive due to HCGbeta-secreting germ cell tumors. Ensure the patient is not pregnant by institutional standards

* Lactating females who plan to breastfeed their infants

* Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation

* All patients and/or their parents or legal guardians must sign a written informed consent

* All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met

Pensi che questo studio appaia erroneamente?

Dettagli del Disegno

AllocazioneNon-Randomized

Modello di InterventoParallel Assignment

MascheramentoNone (Open Label)

Numero da Arruolare240

Bracci e Interventi

Bracci

Interventi

Tipo: Experimental

Descrizione: See Detailed Description.

Interventi:

Carboplatin
Magnetic Resonance Imaging
Questionnaire Administration
Intensity-Modulated Radiation Therapy
Biospecimen Collection
Lumbar Puncture
Intensity-Modulated Proton Therapy
Etoposide
3-Dimensional Conformal Radiation Therapy
Surgical Procedure
3-Dimensional Conformal Proton Radiation Therapy

Misure di Esito

Misure di Esito Primarie

Event-free survival (EFS) (Stratum I)Evaluated at 2- and 3-years post-radiation initiation

Will be estimated for eligible and evaluable patients assigned to Stratum 1 using Kaplan-Meier (KM) EFS estimates at 2 and 3 years with respective 80% two-sided confidence intervals. Time from initiation of radiation to the first occurrence of any of the following events: biochemical or radiographic disease progression, disease recurrence, second malignant neoplasm, or death from any cause.

Misure di Esito Secondarie

EFS (Stratum III)Evaluated at 2- and 3-years post-radiation initiation

Will be estimated for eligible and evaluable patients assigned to Stratum 3 using KM methods at 2 and 3 years with respective 80% two-sided confidence intervals. Time from initiation of radiation to the first occurrence of any of the following events: biochemical or radiographic disease progression, disease recurrence, second malignant neoplasm, or death from any cause.

Radiographic response rateFollowing the completion of Induction therapy, approximately 12 weeks post-chemotherapy initiation

Will report the response rates using the respective sample proportions and exact binomial two-sided 95% confidence intervals.

Marker tumor response rateFollowing the completion of Induction therapy, approximately 12 weeks post-chemotherapy initiation

Will report the response rates using the respective sample proportions and exact binomial two-sided 95% confidence intervals.

Overall survival (OS)Time from initiation of radiation therapy until death by any cause, up to 10 years post-enrollment

Will use KM methods to estimate stratum-specific OS.

EFS (Stratum IV and Stratum V)Evaluated at 2- and 3-years post-radiation initiation

Will be estimated separately for eligible and evaluable patients assigned to Stratum 4 and 5 using KM methods at 2 and 3 years with respective 80% two-sided confidence intervals. Time from initiation of radiation to the first occurrence of any of the following events: biochemical or radiographic disease progression, disease recurrence, second malignant neoplasm, or death from any cause.

EFS (Stratum VI and Stratum VII)Evaluated at 2- and 3-years post-radiation initiation

Will be estimated separately for eligible and evaluable patients assigned to Stratum 6 and 7 using KM methods at 2 and 3 years with respective 80% two-sided confidence intervals. Time from initiation of radiation to the first occurrence of any of the following events: biochemical or radiographic disease progression, disease recurrence, second malignant neoplasm, or death from any cause.

Incidence of cerebral vascular events (stroke or transient ischemic attacks)Up to 10 years post-enrollment

Will be reported as the number of cerebral vascular events.

Working memoryAt 9 months (+/- 3 months), 30 months (+/- 3 months), and 60 months (+/- 3 months) after diagnosis

Will be assessed by Wechsler Intelligence Scale for Children - Fifth Edition (WISC-V) or Wechsler Adult Intelligence Scale - Fourth Edition (WAIS-IV) Digit Span subtest depending on age. Mean scores over time will be computed for each stratum.

Verbal learningAt 9 months (+/- 3 months), 30 months (+/- 3 months), and 60 months (+/- 3 months) after diagnosis

Will be assessed by California Verbal Learning Test - Children's Version for 5 years through 17 years or California Verbal Learning Test - Third for ages 17 and up depending on age. Mean scores over time will be computed for each stratum.

Patient-reported outcome measures of executive functionAt 9 months (+/- 3 months), 30 months (+/- 3 months), and 60 months (+/- 3 months) after diagnosis

Will be assessed by the Behavioral Rating Inventory of Executive Function (BRIEF-2 and BRIEF-A) depending on patient's age. Mean scores over time will be computed for each stratum.

Health-reported quality of lifeAt 9 months (+/- 3 months), 30 months (+/- 3 months), and 60 months (+/- 3 months) after diagnosis

Will be assessed by the PedsQL 4.0 Generic Module. Mean scores over time will be computed for each stratum.

EFS (Stratum II)Evaluated at 2- and 3-years post-radiation initiation

Will be estimated for eligible and evaluable patients assigned to Stratum 2 using KM methods at 2 and 3 years with respective 80% two-sided confidence intervals. Time from initiation of radiation to the first occurrence of any of the following events: biochemical or radiographic disease progression, disease recurrence, second malignant neoplasm, or death from any cause.

Neuroendocrine dysfunction (including growth hormone deficiency)Time from initiation of radiation treatment until date of diagnosis of neuroendocrine dysfunction event, up to 10 years post-enrollment

Will be summarized by the Kalbfleisch-Prentice cumulative incidence function approach, separately by stratum and by neuroendocrine dysfunction event. Competing risks will include disease progression and death, and patients without events or competing risks will be censored at the time of their last follow-up.

Processing speedAt 9 months (+/- 3 months), 30 months (+/- 3 months), and 60 months (+/- 3 months) after diagnosis

Will be assessed by processing speed index tasks for the Wechsler Preschool and Primary Scale of Intelligence - Fourth Edition, Wechsler Intelligence Scale for Children - Fifth Edition (WISC-V) or Wechsler Adult Intelligence Scale - Fourth Edition (WAIS-IV) depending on age. The mean processing speed at 30-months post-diagnosis in ACNS2321 Stratum 1 patients will be compared to the respective mean in ACNS1123 Stratum 2 patients who had a complete response/continued complete response and received 18 grey (Gy) whole ventricle irradiation + 12 Gy boost to primary site.

Aggiungi studio ai preferiti

Condividi Studio

Scarica lo studio

Pensi che questo studio appaia erroneamente?

Segnala Studio

Scarica lo studio

Siti dello Studio

Questo studio ha 108 siti

Newark Beth Israel Medical Center

Newark, New Jersey, US

Nome:Site Public Contact

Email:Christine.Kosmides@rwjbh.org

Telefono:973-926-7230

In fase di reclutamento

Newark, New Jersey, 07112 US

Newark Beth Israel Medical Center

In fase di reclutamento

Dallas, Texas, 75230 US

Medical City Dallas Hospital

In fase di reclutamento

Winnipeg, Manitoba, R3E 0V9 CA

CancerCare Manitoba

In fase di reclutamento

Providence, Rhode Island, 02903 US

Rhode Island Hospital

In fase di reclutamento

Loma Linda, California, 92354 US

Loma Linda University Medical Center

In fase di reclutamento

Maywood, Illinois, 60153 US

Loyola University Medical Center

In fase di reclutamento

Oklahoma City, Oklahoma, 73104 US

University of Oklahoma Health Sciences Center

In fase di reclutamento

Houston, Texas, 77030 US

M D Anderson Cancer Center

In fase di reclutamento

Chicago, Illinois, 60612 US

University of Illinois

In fase di reclutamento

Chicago, Illinois, 60637 US

University of Chicago Comprehensive Cancer Center

In fase di reclutamento

Iowa City, Iowa, 52242 US

University of Iowa/Holden Comprehensive Cancer Center

In fase di reclutamento

Baltimore, Maryland, 21287 US

Johns Hopkins University/Sidney Kimmel Cancer Center

In fase di reclutamento

Boston, Massachusetts, 02215 US

Dana-Farber Cancer Institute

In fase di reclutamento

Minneapolis, Minnesota, 55455 US

University of Minnesota/Masonic Cancer Center

In fase di reclutamento

Jackson, Mississippi, 39216 US

University of Mississippi Medical Center

In fase di reclutamento

Omaha, Nebraska, 68198 US

University of Nebraska Medical Center

In fase di reclutamento

Hackensack, New Jersey, 07601 US

Hackensack University Medical Center

In fase di reclutamento

New York, New York, 10016 US

Laura and Isaac Perlmutter Cancer Center at NYU Langone

In fase di reclutamento

New York, New York, 10029 US

Mount Sinai Hospital

In fase di reclutamento

New York, New York, 10032 US

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center

In fase di reclutamento

New York, New York, 10065 US

Memorial Sloan Kettering Cancer Center

In fase di reclutamento

Syracuse, New York, 13210 US

State University of New York Upstate Medical University

In fase di reclutamento

Chapel Hill, North Carolina, 27599 US

UNC Lineberger Comprehensive Cancer Center

In fase di reclutamento

Winston-Salem, North Carolina, 27157 US

Wake Forest University Health Sciences

In fase di reclutamento

Fargo, North Dakota, 58122 US

Sanford Broadway Medical Center

In fase di reclutamento

San Antonio, Texas, 78229 US

University of Texas Health Science Center at San Antonio

In fase di reclutamento

Toronto, Ontario, M5G 1X8 CA

Hospital for Sick Children

In fase di reclutamento

Honolulu, Hawaii, 96826 US

Kapiolani Medical Center for Women and Children

In fase di reclutamento

Charlottesville, Virginia, 22908 US

University of Virginia Cancer Center

In fase di reclutamento

Hollywood, Florida, 33021 US

Memorial Regional Hospital/Joe DiMaggio Children's Hospital

In fase di reclutamento

Sioux Falls, South Dakota, 57117-5134 US

Sanford USD Medical Center - Sioux Falls

In fase di reclutamento

Dallas, Texas, 75390 US

UT Southwestern/Simmons Cancer Center-Dallas

In fase di reclutamento

Houston, Texas, 77030 US

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center

In fase di reclutamento

Miami, Florida, 33136 US

University of Miami Miller School of Medicine-Sylvester Cancer Center

In fase di reclutamento

New Brunswick, New Jersey, 08903 US

Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital

In fase di reclutamento

New Brunswick, New Jersey, 08901 US

Saint Peter's University Hospital

In fase di reclutamento

Portland, Oregon, 97239 US

Oregon Health and Science University

In fase di reclutamento

Paterson, New Jersey, 07503 US

Saint Joseph's Regional Medical Center

In fase di reclutamento

Spokane, Washington, 99204 US

Providence Sacred Heart Medical Center and Children's Hospital

In fase di reclutamento

Hamilton, Ontario, L8N 3Z5 CA

McMaster Children's Hospital at Hamilton Health Sciences

In fase di reclutamento

Sherbrooke, Quebec, J1H 5N4 CA

Centre Hospitalier Universitaire de Sherbrooke-Fleurimont

In fase di reclutamento

St Louis, Missouri, 63110 US

Washington University School of Medicine

In fase di reclutamento

Las Vegas, Nevada, 89135 US

Alliance for Childhood Diseases/Cure 4 the Kids Foundation

In fase di reclutamento

Las Vegas, Nevada, 89144 US

Summerlin Hospital Medical Center

In fase di reclutamento

Halifax, Nova Scotia, B3K 6R8 CA

IWK Health Centre

In fase di reclutamento

Rochester, Minnesota, 55905 US

Mayo Clinic in Rochester

In fase di reclutamento

San Francisco, California, 94158 US

UCSF Medical Center-Mission Bay

In fase di reclutamento

Tampa, Florida, 33607 US

Saint Joseph's Hospital/Children's Hospital-Tampa

In fase di reclutamento

Pittsburgh, Pennsylvania, 15224 US

Children's Hospital of Pittsburgh of UPMC

In fase di reclutamento

Little Rock, Arkansas, 72202-3591 US

Arkansas Children's Hospital

In fase di reclutamento

Los Angeles, California, 90027 US

Children's Hospital Los Angeles

In fase di reclutamento

Orange, California, 92868 US

Children's Hospital of Orange County

In fase di reclutamento

San Diego, California, 92123 US

Rady Children's Hospital - San Diego

In fase di reclutamento

Aurora, Colorado, 80045 US

Children's Hospital Colorado

In fase di reclutamento

Wilmington, Delaware, 19803 US

Alfred I duPont Hospital for Children

In fase di reclutamento

Miami, Florida, 33155 US

Nicklaus Children's Hospital

In fase di reclutamento

Chicago, Illinois, 60611 US

Lurie Children's Hospital-Chicago

In fase di reclutamento

Indianapolis, Indiana, 46202 US

Riley Hospital for Children

In fase di reclutamento

Ann Arbor, Michigan, 48109 US

C S Mott Children's Hospital

In fase di reclutamento

Minneapolis, Minnesota, 55404 US

Children's Hospitals and Clinics of Minnesota - Minneapolis

In fase di reclutamento

Cleveland, Ohio, 44106 US

Rainbow Babies and Childrens Hospital

In fase di reclutamento

Columbus, Ohio, 43205 US

Nationwide Children's Hospital

In fase di reclutamento

Philadelphia, Pennsylvania, 19104 US

Children's Hospital of Philadelphia

In fase di reclutamento

Columbia, South Carolina, 29203 US

Prisma Health Richland Hospital

In fase di reclutamento

Austin, Texas, 78723 US

Dell Children's Medical Center of Central Texas

In fase di reclutamento

Salt Lake City, Utah, 84113 US

Primary Children's Hospital

In fase di reclutamento

Norfolk, Virginia, 23507 US

Children's Hospital of The King's Daughters

In fase di reclutamento

Seattle, Washington, 98105 US

Seattle Children's Hospital

In fase di reclutamento

Greenville, South Carolina, 29605 US

BI-LO Charities Children's Cancer Center

In fase di reclutamento

Perth, Western Australia, 6009 AU

Perth Children's Hospital

In fase di reclutamento

Mobile, Alabama, 36604 US

USA Health Strada Patient Care Center

In fase di reclutamento

Phoenix, Arizona, 85016 US

Phoenix Childrens Hospital

In fase di reclutamento

Palo Alto, California, 94304 US

Lucile Packard Children's Hospital Stanford University

In fase di reclutamento

Hartford, Connecticut, 06106 US

Connecticut Children's Medical Center

In fase di reclutamento

Jacksonville, Florida, 32207 US

Nemours Children's Clinic-Jacksonville

In fase di reclutamento

Orlando, Florida, 32806 US

Arnold Palmer Hospital for Children

In fase di reclutamento

Orlando, Florida, 32827 US

Nemours Children's Hospital

In fase di reclutamento

Pensacola, Florida, 32504 US

Nemours Children's Clinic - Pensacola

In fase di reclutamento

Louisville, Kentucky, 40202 US

Norton Children's Hospital

In fase di reclutamento

Kansas City, Missouri, 64108 US

Children's Mercy Hospitals and Clinics

In fase di reclutamento

Omaha, Nebraska, 68114 US

Children's Hospital and Medical Center of Omaha

In fase di reclutamento

Albany, New York, 12208 US

Albany Medical Center

In fase di reclutamento

New Hyde Park, New York, 11040 US

The Steven and Alexandra Cohen Children's Medical Center of New York

In fase di reclutamento

Philadelphia, Pennsylvania, 19134 US

Saint Christopher's Hospital for Children

In fase di reclutamento

Corpus Christi, Texas, 78411 US

Driscoll Children's Hospital

In fase di reclutamento

San Antonio, Texas, 78207 US

Children's Hospital of San Antonio

In fase di reclutamento

Hunter Regional Mail Centre, New South Wales, 2310 AU

John Hunter Children's Hospital

In fase di reclutamento

Randwick, New South Wales, 2031 AU

Sydney Children's Hospital

In fase di reclutamento

Westmead, New South Wales, 2145 AU

The Children's Hospital at Westmead

In fase di reclutamento

Parkville, Victoria, 3052 AU

Royal Children's Hospital

In fase di reclutamento

Edmonton, Alberta, T6G 2B7 CA

University of Alberta Hospital

In fase di reclutamento

Vancouver, British Columbia, V6H 3V4 CA

British Columbia Children's Hospital

In fase di reclutamento

London, Ontario, N6A 5W9 CA

Children's Hospital

In fase di reclutamento

Montreal, Quebec, H3H 1P3 CA

The Montreal Children's Hospital of the MUHC

In fase di reclutamento

Montreal, Quebec, H3T 1C5 CA

Centre Hospitalier Universitaire Sainte-Justine

In fase di reclutamento

South Brisbane, Queensland, 4101 AU

Queensland Children's Hospital

In fase di reclutamento

Memphis, Tennessee, 38105 US

Saint Jude Children's Research Hospital

In fase di reclutamento

Boise, Idaho, 83712 US

Saint Luke's Cancer Institute - Boise

In fase di reclutamento

Oakland, California, 94609 US

UCSF Benioff Children's Hospital Oakland

In fase di reclutamento

Lebanon, New Hampshire, 03756 US

Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center

In fase di reclutamento

Madison, Wisconsin, 53792 US

University of Wisconsin Carbone Cancer Center - University Hospital

In fase di reclutamento

Grand Rapids, Michigan, 49503 US

Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital

In fase di reclutamento

Atlanta, Georgia, 30329 US

Children's Healthcare of Atlanta - Arthur M Blank Hospital

In fase di reclutamento

St. Petersburg, Florida, 33701 US

Johns Hopkins All Children's Hospital

In fase di reclutamento

The Bronx, New York, 10467 US

Montefiore Medical Center - Moses Campus

In fase di reclutamento

Washington D.C., District of Columbia, 20010 US

Children's National Medical Center

In fase di reclutamento

Québec, G1V 4G2 CA

CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL)

In fase di reclutamento

St Louis, Missouri, 63104 US

Cardinal Glennon Children's Medical Center

Loading Maps...